ApicHope Pharmaceutical Group (300723.SZ) subsidiary's innovative drug APH04935 tablets receive U.S. FDA clinical trial approval.
ApicHope Pharmaceutical Group (300723.SZ) announced that recently, its wholly-owned subsidiary Guangzhou ApicHope Pharmaceutical Co., Ltd. ("ApicHope Pharmaceutical") received a letter from the U.S. Food and Drug Administration (FDA) approving the clinical trial of APH04935 tablets, an innovative drug independently developed by the company's subsidiary.
ApicHope Pharmaceutical Group (300723.SZ) announced that recently, its wholly-owned subsidiary Guangzhou ApicHope Pharmaceutical Group Pharmaceutical Co., Ltd. (referred to as "ApicHope Pharmaceutical Group Pharmaceutical") received a letter from the U.S. Food and Drug Administration (FDA) approving the clinical trial of APH04935 tablets, an innovative drug independently developed by the company's subsidiary.
APH04935 tablets are a highly active and highly selective small-molecule GLP-1R (full name: Glucagon-like Peptide-1 Receptor) agonist independently developed by the company, targeting to become a once-daily oral small-molecule GLP-1R agonist, intended for weight control and long-term weight management.
Related Articles
VPOWER GROUP (01608): The adjourned convening hearing will be rescheduled to October 21.
ZTO EXPRESS-W (02057) repurchased approximately 233,900 shares for approximately US$4.6298 million on October 7.
MNSO (09896) repurchased approximately 109,900 shares for approximately US$245,900 on October 7.
VPOWER GROUP (01608): The adjourned convening hearing will be rescheduled to October 21.
ZTO EXPRESS-W (02057) repurchased approximately 233,900 shares for approximately US$4.6298 million on October 7.
MNSO (09896) repurchased approximately 109,900 shares for approximately US$245,900 on October 7.
